Capricor Therapeutics remains optimistic about FDA approval for Deramiocel, despite a recent Form 483 observation and an ongoing dispute with NS Pharma. The company's stock surged premarket on this news, indicating investor confidence in its ability to navigate regulatory and commercial challenges.
Capricor Therapeutics provided an update on its Biologics License Application (BLA) for Deramiocel, indicating active engagement with the FDA and addressing a Form 483 observation. This news, coupled with the company's operational manufacturing facility and strong cash position, suggests a positive outlook for the drug's approval and commercial launch. The ongoing dispute with NS Pharma and the measured pace of commercial readiness introduce some uncertainty, but the premarket stock surge indicates that investors are focusing on the potential upside of FDA approval. For traders, this presents a short-term opportunity based on regulatory clarity, with long-term implications tied to successful market penetration and resolution of the NS Pharma dispute.